Cargando…
A selective BCL-X(L) PROTAC degrader achieves safe and potent antitumor activity
BCL-X(L) is a well-validated cancer target. However, the on-target and dose-limiting thrombocytopenia limits the use of BCL-X(L) inhibitors such as ABT263 as safe and effective anticancer agents. To reduce the toxicity of ABT263, we converted it into DT2216, a BCL-X(L) proteolysis targeting chimera...
Autores principales: | Khan, Sajid, Zhang, Xuan, Lv, Dongwen, Zhang, Qi, He, Yonghan, Zhang, Peiyi, Liu, Xingui, Thummuri, Dinesh, Yuan, Yaxia, Wiegand, Janet S., Pei, Jing, Zhang, Weizhou, Sharma, Abhisheak, McCurdy, Christopher R., Kuruvilla, Vinitha M., Baran, Natalia, Ferrando, Adolfo A., Kim, Yong-mi, Rogojina, Anna, Houghton, Peter J., Huang, Guangcun, Hromas, Robert, Konopleva, Marina, Zheng, Guangrong, Zhou, Daohong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6898785/ https://www.ncbi.nlm.nih.gov/pubmed/31792461 http://dx.doi.org/10.1038/s41591-019-0668-z |
Ejemplares similares
-
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
por: He, Yonghan, et al.
Publicado: (2020) -
PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
por: Khan, Sajid, et al.
Publicado: (2020) -
PROTACs are effective in addressing the platelet toxicity associated with BCL-X(L) inhibitors
por: Zhang, Peiyi, et al.
Publicado: (2020) -
Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,
por: Lv, Dongwen, et al.
Publicado: (2021) -
Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity
por: He, Yonghan, et al.
Publicado: (2020)